Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
3rd December 2020 | Franklin M Berger | 6,534 | Exercise of derivative | $4.00 | $26,136.00 |
3rd December 2020 | Franklin M Berger | 2,184 | Exercise of derivative | $3.81 | $8,321.04 |
3rd December 2020 | Franklin M Berger | 6,773 | Exercise of derivative | $4.67 | $31,629.91 |
3rd December 2020 | Franklin M Berger | 25,000 | Exercise of derivative | $3.23 | $80,750.00 |
3rd December 2020 | Franklin M Berger | 1,716 | Exercise of derivative | $4.00 | $6,864.00 |
11th June 2020 | Franklin M Berger | 100,000 | Open or private purchase | $5.50 | $550,000.00 |
11th June 2020 | Talent Investments Ltd Equal | 1,454,545 | Open or private purchase | $5.50 | $7,999,997.50 |
4th February 2020 | Christopher J. Kirk | 38,461 | Open or private purchase | $2.60 | $99,998.60 |
4th February 2020 | Venture Investments Ltd Morningside | 3,800,000 | Open or private purchase | $2.60 | $9,880,000.00 |
4th February 2020 | Franklin M Berger | 120,846 | Open or private purchase | $2.60 | $314,199.60 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company. The firm specializes in the areas of protein degradation and protein secretion. Its product include KZR-616, an immunoproteasome inhibitor.
6th November 2020
6th November 2020
6th November 2020
6th November 2020